Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Out of REACH: New legislation threatens medicines

20.11.2006
Europe’s proposed new chemicals legislation, REACH, could disrupt the supply of important medicines.

David Vosvenieks, REACH issue manager at AstraZeneca (AZ), told Chemistry & Industry that two companies supplying intermediates required for two AZ drugs – one of them an anticancer therapy– have already warned AZ that they may no longer be able to guarantee supply under the new rules. Pfizer and GlaxoSmithKline have also said they are in discussions with suppliers.

REACH, which could come into force next April, poses a serious threat to supplies of large numbers of intermediates and raw materials used in drug manufacture. ‘While the possibility of this happening has always been on our radar, this has come as a rude awakening,’ Vosvenieks said.

A change in supplier would mean re-submitting a drug for evaluation by the regulatory authorities. And because a lot of current manufacture is driven by demand, many drug companies would not have stockpiles to cover the re-authorisation period, which according to the UK Medicines and Healthcare products Regulatory Authority could take up to two months. In the worst-case scenario this could mean a delay with restarting supply.

... more about:
»REACH »Vosvenieks

A spokesman for Pfizer, the world’s largest pharmaceutical company, admitted the company was also in discussions with suppliers over REACH, but declined to say whether any particular products were affected. GSK is also reviewing suppliers, but a spokesman said that they had not come up against any problems to date.

‘Finding a new supplier would be very much a last resort, and would potentially bring extra costs,’ Vosvenieks said. Pharmaceutical active ingredients (APIs) are largely exempt from REACH, but many of the solvents and intermediates involved in the manufacture of the final drug formulation will not be. The main chemicals affected will be hazardous chemicals such as carcinogens or mutagens. ‘Such compounds may be used in 5 -10% of drug syntheses as a very rough estimate,’ according to Vosvenieks.

Many of the smaller or more specialist firms producing them may lack the resources to comply with REACH.

SCI press | alfa
Further information:
http://www.soci.org
http://www.chemind.org

Further reports about: REACH Vosvenieks

More articles from Life Sciences:

nachricht Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg

nachricht Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>